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Abstract Open-angle glaucoma (OAG) is the commonest
cause of irreversible blindness worldwide. Apart from an
increased intraocular pressure (IOP), oxidative stress and an
impaired ocular blood flow are supposed to contribute to
OAG. The aim of this study was to determine whether the
dietary intake of nutrients that either have anti-oxidative
properties (carotenoids, vitamins, and flavonoids) or influence
the blood flow (omega fatty acids and magnesium) is associ-
ated with incident OAG. We investigated this in a prospective
population-based cohort, the Rotterdam Study. A total of 3502
participants aged 55 years and older for whom dietary data at
baseline and ophthalmic data at baseline and follow-up were
available and who did not have OAG at baseline were inclu-
ded. The ophthalmic examinations comprised measurements
of the IOP and perimetry; dietary intake of nutrients was
assessed by validated questionnaires and adjusted for energy
intake. Cox proportional hazard regression analysis was
applied to calculate hazard ratios of associations between the
baseline intake of nutrients and incident OAG, adjusted for
age, gender, IOP, IOP-lowering treatment, and body mass
index. During an average follow-up of 9.7 years, 91 partici-
pants (2.6%) developed OAG. The hazard ratio for retinol
equivalents (highest versus lowest tertile) was 0.45 (95%
confidence interval 0.23–0.90), for vitamin B1 0.50
(0.25–0.98), and for magnesium 2.25 (1.16–4.38). The effects
were stronger after the exclusion of participants taking sup-
plements. Hence, a low intake of retinol equivalents and
vitamin B1 (in line with hypothesis) and a high intake of
magnesium (less unambiguous to interpret) appear to be
associated with an increased risk of OAG.
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Introduction
One of the most important sight-threatening eye disorders
in ophthalmology is open-angle glaucoma (OAG). This
progressive neurodegenerative disease leads to glaucoma-
tous optic neuropathy and eventually, through glaucoma-
tous visual field loss, to loss of sight. Together with age-
related macular degeneration it is the most common cause
of irreversible blindness.
An increased intraocular pressure (IOP) is the main risk
factor for OAG, but IOP-independent mechanisms play a
role as well: some people develop OAG without an
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elevated IOP and in others the deterioration continues
despite an apparently sufficient reduction of the IOP. Neu-
rodegeneration and an impaired ocular blood flow are
examples of mechanisms supposed to contribute to the IOP-
independent deterioration in OAG; oxidative stress is pre-
sumed to be part of the neurodegenerative process [1–4].
Apart from its neurodegenerative effect on the optic nerve,
oxidative stress has also been suggested to damage the tra-
becular meshwork, resulting in an increase in the IOP [2]. For
these reasons, the effects of nutrients with anti-oxidant
activity are of great interest [5], especially because the intake
of nutrients is modifiable. It has been shown that differences
in intake of anti-oxidants may influence the course of an eye
disease (e.g., age-related macular degeneration), even in the
western world without apparent malnutrition [6, 7]. Com-
mon nutrients with anti-oxidant activity are carotenoids
(present in most fruits and vegetables), retinol equivalents,
vitamins B, C and E, and polyphenolic flavonoids (present in
tea, especially green tea, and coffee).
The second presumed mechanism for an IOP-indepen-
dent deterioration in OAG was an impaired blood flow.
Nutrients of interest here are the omega-3 and omega-6
fatty acids, and magnesium. The fatty acids are well known
in the cardiovascular literature because of their effect on
blood flow regulation by serving as direct precursors of
prostaglandins. It has been suggested that they may be of
therapeutic value in OAG [8, 9]. Previous studies suggested
that magnesium may play a role in the pathogenesis of
OAG by affecting the peripheral circulation [10]. Thus far,
the possible role of nutrients in OAG was addressed only in
the Nurses’ Health Study (see ‘‘Discussion’’) [11–13].
The aim of the present study was to explore the influence
of nutrients that either have anti-oxidant activity or influence
the (ocular) blood flow on the development of OAG. For this
purpose, we studied the associations between the intakes of
these nutrients and incident OAG in a prospective popula-
tion-based setting. As there may be effects both directly on
the optic nerve and through the IOP, we also studied the
associations between these intakes and the IOP.
Methods
Participants
The present study was performed within the Rotterdam Study,
a prospective population-based cohort study comprising 7,983
residents aged 55 years and older living in Ommoord, a dis-
trict of Rotterdam, the Netherlands [14]. The baseline exam-
ination of the ophthalmic part of the Rotterdam Study
included 6,806 participants and took place between 1991 and
1993; follow-up examinations for OAG were performed from
1997 to 1999 and from 2002 to 2006. Participants were
included in this study if they (1) participated both at baseline
and at least at one follow-up examination, (2) had complete
data on OAG and dietary intake, and (3) were not classified as
having OAG at baseline. All measurements were conducted
after the Medical Ethics Committee of the Erasmus University
had approved the study protocol and all participants had given
a written informed consent in accordance with the Declaration
of Helsinki.
Ophthalmic examination
The examinations at baseline and follow-up included au-
torefraction (Topcon RM-A2000; Tokyo Optical Co.,
Tokyo, Japan), keratometry (Topcon OM-4 Ophthalmom-
eter; Tokyo Optical Co., Tokyo, Japan), measurement of
the best corrected visual acuity with ETDRS optotypes,
measurement of the IOP (see below), fundus photography
of the posterior pole (Topcon TRC-50VT, Tokyo Optical
Co., Tokyo, Japan), simultaneous stereoscopic fundus
photography of the optic nerve head (Topcon ImageNet
System, Topcon TRC-SS2, Tokyo Optical Co., Tokyo,
Japan), imaging of the optic nerve head with the Heidelberg
Retina Tomograph (Heidelberg Engineering, Dossenheim,
Germany) and visual field testing (HFA II 740; Zeiss,
Oberkochen, Germany; see below).
The IOP was measured at baseline and at every follow-up
round with Goldmann applanation tonometry (Haag-Streit
AG, Bern, Switzerland) after applying oxybuprocaine
0.4% eye drops and fluorescein from a paper strip. Three
measurements were taken on each eye and the median value
of these three measurements was recorded [15]. In the
analysis we used the highest IOP of both eyes.
The visual field of each eye was screened using a
52-point supra-threshold test that covered the central visual
field with a radius of 24 [16, 17]. Visual field loss was
defined as non-response in at least three contiguous test
points (or four including the blind spot). In participants
with reproducible abnormalities on supra-threshold testing,
Goldmann perimetry (Haag-Streit AG, Bern, Switzerland;
baseline and first follow-up) or a full-threshold HFA 24-2
test (second follow-up) was performed on both eyes.
Details about the classification process were described
before [16, 18]. Cases had to have an open anterior
chamber angle; a history or signs of secondary glaucoma
were not allowed.
Incident OAG was defined as no glaucomatous visual
field loss in both eyes at baseline and glaucomatous visual
field loss in at least one eye at follow-up [18].
Assessment of nutrient intake
All participants were interviewed at baseline for food
assessment using an extensive semiquantitative food
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frequency questionnaire at the study center by a trained
dietician. The questionnaire was validated and adapted for
use in the elderly [19–21]. It contains 170 food items in 13
food groups and questions about dietary habits and sup-
plementation. The dietary intake of nutrients was calcu-
lated using The Dutch Food Composition Database
(NEVO) from 1993 to 2006. ‘‘Energy-adjusted’’ nutrient
intakes were computed as the unstandardized residuals
from a (linear) regression model in which total caloric
intake served as the independent variable and the absolute
nutrient intake as the dependent variable. Because residuals
have a mean of zero and thus include negative values, the
expected mean nutrient intakes of the study population was
added to the residuals as derived from the regression
analysis [22]. Next, we divided the energy-adjusted intake
into tertiles (low, medium, and high intake). This process
was repeated for all nutrients.
Included nutrients were those that have anti-oxidative
properties, being carotenoids (a-carotene, ß-carotene,
lutein, zeaxanthin, ß-cryptoxanthin and lycopene), vitamins
(retinol equivalents, B1, B6, B12, E and C) and flavonoids,
and those that influence the blood flow, being omega-3
fatty acids (a-linolenic acid [ALA; C18:3 (n-3) cis], eico-
sapentaenoic acid [EPA; C20:5 (n-3) cis], docosahexaenoic
acid [DHA; C22:6 (n-3) cis]), omega-6 fatty acids (linoleic
acid [LA; C18:2 (n-6) cis]) and magnesium. Calcium and
phosphorus were included because they compete with
magnesium absorption.
As there are two sources of dietary vitamin A (active
forms and provitamins), we expressed the amounts of
vitamin A in retinol equivalents.
Body mass index was calculated as weight in kilograms
divided by height in meters squared. Weight and height
were measured at the research center.
Statistical analysis
Differences in baseline characteristics were analyzed with
independent t tests and Chi-square statistics. Nutrients with
p \ 0.10 in the univariate comparisons (between partici-
pants with and without incident OAG) were included in a
multivariate analysis. For the latter, we used a Cox pro-
portional hazard model to calculate hazard ratios (HR) with
corresponding 95% confidence intervals (CI) to analyze
whether participants had a lower or higher risk of incident
OAG. Follow-up duration was used as the time variable.
Follow-up duration was counted from the baseline visit to
the last visit with reliable perimetry. Incident OAG cases
were censored at the first visit in which glaucomatous
visual field loss was detected. The model was adjusted for
age, gender, IOP, IOP-lowering treatment and body mass
index, all measured at baseline. Adjustment for IOP was
done to analyse whether the effects of the nutrients were
independent of IOP. For each nutrient, the lowest tertile
(i.e., the participants with the lowest intake) served as the
reference group. Tertiles were analyzed as nominal cate-
gories, that is, we did not assume beforehand monotonic
relationships between nutrient intakes and outcome mea-
sure. To evaluate these relationships, linearity was tested
by calculating the p-trend for the nutrients that showed a
significant association with OAG in the final model. We
also explored whether there was interaction between age or
gender and each of the nutrients from the final model. As a
secondary analysis, we repeated the above-mentioned
analysis after exclusion of participants who reported to
have used any supplements (vitamins or other health pills)
at baseline.
To assess the associations between nutrients and IOP,
we performed for each nutrient a linear regression analysis
(IOP at follow up versus intake). These analyses were
adjusted for IOP-lowering treatment at follow-up. Nutri-
ents were analyzed as nominal categories (see above).
Nutrients with p \ 0.10 were included in a multiple linear
regression analysis with IOP at follow-up as the dependent
variable. This model was adjusted for age, gender, body
mass index, and IOP-lowering treatment during follow-up.
We used complete case analysis and considered a p value
of 0.05 or less statistically significant. All statistical analyses
were performed using SPSS version 15.0.0 for Windows
(SPSS inc., Chicago, IL, USA; 2006) and R statistical
package version 2.11.1 for Mac (http://www.r-project.org).
Results
A total of 6,806 participants attended the baseline exam-
inations of the ophthalmic part of the Rotterdam Study.
From these participants, 6,630 did not have OAG at
baseline and 3,939 of 6,630 (59.4%) completed at least one
follow-up round (1,279 died before the first follow-up
round, 1473 were unable to participate in the first follow-up
round and 143 had unreliable data with regard to OAG; of
the participants without (reliable) data at the first follow-up
round, 204 successfully completed the second follow-up
round). Of these 3,939 participants, 437 did not have reli-
able data of the food frequency questionnaire or supple-
ment use. This resulted in 3,502 eligible participants for the
current study.
During a mean follow-up of 9.7 years (range
5.3–13.9 years), 91 (2.6%) developed OAG. Table 1 sum-
marizes the general characteristics of the study population at
baseline according to incident OAG status. Participants who
developed OAG were significantly older, more often men,
and had a lower body mass index than those without incident
OAG. Their use of supplements did not differ from that of
participants without incident OAG (p = 0.86).
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Table 2 shows the descriptive data of the mean daily
dietary intake of nutrients for all participants adjusted for
total energy intake, with corresponding univariate com-
parisons between participants with and without incident
OAG. At the p \ 0.10 level, participants with incident
OAG had a lower intake of ß-carotene, retinol equivalents,
vitamin B1 and vitamin B12, and a higher intake of mag-
nesium and vitamin E compared to participants without
incident OAG. No other differences in nutrition were found
between participants with and without incident OAG.
Table 3 shows the results of the multivariate analysis, both
for all participants and after exclusion of participants using
supplements. High intakes of retinol equivalents and vita-
min B1 were associated with a decreased risk of OAG,
whereas a high intake of magnesium was associated with
an increased risk. For these nutrients the crude hazard
ratios (that is, only adjusted for age) were statistically
significant as well (p = 0.019, p = 0.047, and p = 0.014
for high intake of retinol equivalents, vitamin B1 and
magnesium, respectively). The p-trend for retinol equiva-
lents was 0.018, for vitamin B1 0.042, and for magnesium
0.014. We found no significant interactions between age or
gender and the nutrients. The effects were stronger if we
excluded participants using supplements.
As mentioned in the Introduction, factors may affect the
optic nerve head in OAG directly or through the IOP. In the
latter case, IOP is in the causal pathway. Although the
hypotheses suggest IOP-independent mechanisms for the
effects of nutrient intake on OAG, we repeated our anal-
yses without adjustment for IOP and also studied the role
of IOP separately. The results of our primary analysis
(Table 3) did not change after removing IOP from the
model, i.e., the effects appeared to be IOP independent. In
the multiple linear regression analysis, there were signifi-
cant associations for a medium intake of ß-cryptoxanthin
(beta: -0.35 mmHg; p = 0.049) and a medium intake of
vitamin B12 (beta: -0.35 mmHg; p = 0.039) with IOP. A
high intake of these two nutrients, however, was not sig-
nificantly associated with IOP, precluding the presence of a
clear dose–response relationship.
Discussion
Retinol equivalents and vitamin B1 seem to have a pro-
tective effect on OAG, whereas magnesium intake appears
to be associated with an increased risk. Since the analyses
were adjusted for IOP, these effects should be considered
IOP-independent. This is in agreement with the fact that we
did not find a significant effect of these nutrients on IOP.
None of the other nutrients had an unequivocal effect on
IOP as well. The effects of retinol equivalents, vitamin B1
and magnesium on OAG became stronger when excluding
participants taking supplements.
Little is known about the possible associations between
nutrition and OAG. The Nurses’ Health Study and the Health
Professionals Follow-up Study, two large prospective cohorts
comprising over 100,000 participants, studied the influence of
nutrients with anti-oxidative properties on OAG. They could
not find a significant association [11]. Our results on anti-
oxidants (with the exception of vitamin A) were in line with
their results (no significant effect on OAG). A possible
explanation for the non-significant finding of vitamin A in
their study might be that their OAG cases were based on self-
report. After all, glaucoma is an insidious eye disease and
about half of the OAG patients are undetected at a certain
moment [17, 23]. This may cause a selection bias in studies
based on self-report (or studies performed in a clinical envi-
ronment). Our population-based approach in which the OAG
cases were detected by systematic screening only should be
robust with regard to such a selection bias. A striking differ-
ence between the Nurses’ Health and Health Professional
Follow-up Study and our study is a difference in baseline IOP:
75.5% of the participants in the Nurses’ Health and Health
Professional Follow-up Study had an IOP [ 22 mmHg
compared to only 15.4% in our study. Furthermore, partici-
pants of the Nurses’ Health Study and the Health Professional
Follow-up Study were younger (30–75 years; mean age
*49 years) compared to those from the current study
([55 years; mean age 65.2 years). Dietary intake, metabo-
lism, and absorption of nutrients are different in the elderly.
The effect of vitamin A on the development of OAG may be
different in young people developing high-tension glaucoma
compared to elderly people developing normal-tension glau-
coma. Unfortunately, power limitations inhibited the conduct
of interaction analyses between vitamin A, baseline IOP and
age. Of interest is that vitamin A and retinoic acid (a metab-
olite of vitamin A) were shown to have a therapeutic effect in
Table 1 Baseline characteristics and univariate analyses of the study
population with and without incident open-angle glaucoma presented
as mean ± standard deviation (range) unless stated otherwise
Incident
open-angle
glaucoma
(N = 91)
No open-
angle
glaucoma
(N = 3411)
p value
Age (year) 67.6 ± 7.0 65.1 ± 6.6 \0.001
Gender (N[%] female) 47 (51.6) 2031 (59.5) 0.13
IOP (mmHg) 17.5 ± 4.8 15.0 ± 3.1 \0.001
IOP-lowering
treatment (N[%])
14 (15.4) 73 (2.1) \0.001
Body mass index (kg/m2) 25.5 ± 2.9 26.3 ± 3.5 0.03
Supplement users (N[%]) 33 (36.3) 1269 (37.2) 0.86
Diabetes mellitus (N[%]) 6 (6.6) 126 (3.7) 0.16
IOP intraocular pressure
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Alzheimer’s disease, like OAG a neurodegenerative disorder
[24, 25]. This effect may be due to the anti-amyloidogenic
properties of retinoic acid (and vitamin A) [26]. Several
studies implicated amyloid-beta deposition in Alzheimer’s
disease. It has been shown that amyloid-beta is involved in
retinal ganglion cell apoptosis in OAG [27]. In animals, reti-
noic acid plays a role in optic nerve regeneration after injury
[28]. Food sources rich in retinol equivalents are dairy prod-
ucts (milk, cheese, butter) and liver.
Patients with OAG are reported to have a lower thiamine
(vitamin B1) level than controls [29]. This supports the
current finding of a protective effect of vitamin B1. We
showed the protective effect of vitamin B1 on OAG to be
independent of IOP. This is in agreement with the associ-
ation between vitamin B1 deficiency and degeneration of
ganglion cells of the brain and spinal cord in animal
experiments [30], and between vitamin B1 deficiency and a
reduced thickness of the retinal ganglion cell layer in rats
Table 2 Mean dietary intake of the assessed nutrients by tertile (low, medium and high intake), adjusted for total energy intake for each tertile,
with corresponding univariate comparisons between participants with and without incident open-angle glaucoma
Nutrient Low intake Medium intake High intake p value*
Mean ± SD Range Mean ± SD Range Mean ± SD Range
With anti-oxidative properties
a-carotene
(lg/day)
590.72 ± 205.44 (\852.18) 1059.18 ± 119.34 (852.40–1278.48) 1851.95 ± 996.30 ([1278.76) 0.438
ß-carotene
(lg/day)
2431.61 ± 613.88 (\3216.03) 3775.53 ± 334.72 (3219.18–4399.33) 5879.44 ± 2609.44 ([4399.61) 0.075
Lutein (lg/day) 1417.24 ± 318.64 (\1842.51) 2164.79 ± 188.46 (1842.72–2504.99) 3235.32 ± 1156.42 ([2506.38) 0.238
Zeaxanthin
(lg/day)
72.54 ± 17.16 (\96.48) 117.06 ± 11.85 (96.49–137.88) 175.99 ± 46.14 ([137.89) 0.865
ß-cryptoxanthin
(lg/day)
74.77 ± 53.60 (\173.59) 265.80 ± 61.07 (174.27–371.22) 530.05 ± 191.52 ([371.31) 0.809
Retinol
equivalents
(mg/day)
0.57 ± 0.10 (\0.68) 0.76 ± 0.04 (0.68–0.84) 1.11 ± 0.46 ([0.84) 0.003
Vitamin B1
(mg/day)
0.87 ± 0.11 (\1.01) 1.11 ± 0.06 (1.01–1.22) 1.39 ± 0.15 ([1.22) 0.017
Vitamin B6
(mg/day)
1.31 ± 0.14 (\1.47) 1.59 ± 0.07 (1.47–1.70) 1.92 ± 0.21 ([1.70) 0.988
Vitamin B12
(mg/day)
2.78 ± 0.75 (\3.69) 4.33 ± 0.39 (3.70–5.07) 8.48 ± 6.92 ([5.08) 0.066
Vitamin C
(mg/day)
72.07 ± 17.17 (\96.49) 114.99 ± 10.87 (96.50–134.74) 177.97 ± 45.30 ([134.79) 0.956
Vitamin E
(mg/day)
8.83 ± 1.99 (\11.38) 13.29 ± 1.13 (11.38–15.33) 19.42 ± 4.04 ([15.35) 0.086
Flavonoids 16.52 ± 4.77 (\23.09) 27.94 ± 2.89 (23.10–33.23) 42.18 ± 8.70 ([33.23) 0.923
Affecting blood flow
ALA (C18:3
(n-3) cis) (g/day)
0.62 ± 0.14 (\0.81) 0.95 ± 0.09 (0.81–1.12) 1.56 ± 0.44 ([1.12) 0.470
EPA (C20:5 (n-3)
cis) (g/day)
0.00 ± 0.01 (\0.01) 0.03 ± 0.01 (0.01–0.05) 0.11 ± 0.09 ([0.05) 0.729
DHA (C22:6
(n-3) cis) (g/day)
0.02 ± 0.01 (\0.04) 0.07 ± 0.02 (0.04–0.10) 0.21 ± 0.14 ([0.11) 0.704
LA (C18:2 (n-6)
cis) (g/day)
6.37 ± 2.47 (\9.47) 12.04 ± 1.56 (9.48–14.94) 19.87 ± 4.54 ([14.94) 0.410
Calcium (mg/day) 773.27 ± 149.99 (\964.91) 1095.41 ± 76.58 (965.19–1238.44) 1527.75 ± 285.00 ([1238.61) 0.358
Phosphorus
(mg/day)
1117.50 ± 144.93 (\1319.64) 1515.03 ± 130.32 (1320.59–1786.33) 2498.47 ± 777.77 ([1787.00) 0.865
Magnesium
(mg/day)
252.94 ± 28.63 (\287.87) 309.41 ± 12.38 (287.88–331.51) 369.48 ± 34.67 ([331.52) 0.001
* p Values of the univariate analyses between participants with and without incident open-angle glaucoma
sd standard deviation, ALA a-linolenic acid, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, LA linoleic acid
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[31]. Furthermore, a link between vitamin B1 deficiency
and other optic neuropathies is well established [32].
Obviously, most participants with a low intake of vitamin
B1 in the current study may not have had a manifest
vitamin B1 deficiency. Alcohol consumption could be a
confounder here, but alcohol consumption was not asso-
ciated with either IOP or OAG [33]. Recently, a synthetic
derivative of vitamin B1, sulbutiamine, has been shown to
have a neuroprotective effect on retinal ganglion cells,
probably due to its anti-apoptotic properties [34]. Food
sources rich in vitamin B1 are grain products (bread, rice)
and potatoes.
Regarding nutrients affecting blood flow, the Nurses’
Health Study and the Health Professionals Follow-up Study
showed an increased risk of OAG in participants with a
high ratio of omega-3 to omega-6 polyunsaturated fat
(relative risk [95% CI]: 1.49 [1.11–2.01]) [12]. However,
the latter association was only present in participants with
high-tension OAG (OAG with IOP [ 21 mmHg; relative
risk [95% CI]: 1.68 [1.18–2.40]) and not in participants
with normal-tension OAG (OAG with IOP B 21 mmHg;
relative risk [95% CI]: 0.82 [0.20–3.47]). The ratio of
omega-3 to omega-6, adjusted for total energy intake, was
in our study higher in participants with OAG (mean 0.19)
compared to participants without OAG (0.12), but this
difference did not reach statistical significance (p = 0.22).
This lack of significance might be explained by power
limitations or by the fact that the majority (79%) of our
incident OAG cases had an IOP B 21 mmHg and were
untreated at baseline. The corresponding small number of
cases with an IOP [ 21 mmHg or on IOP-lowering treat-
ment at baseline hampers a secondary subgroup analysis.
A review of natural therapies (that is, by means of
changing nutrition habits) for ocular disorders highlighted
the role of magnesium supplementation in OAG therapy
[30]. Magnesium administration improves the peripheral
circulation [35] and has been reported to have a beneficial
effect on the visual field in patients with OAG with cold-
induced vasospasm [10]. However, there are some con-
cerns regarding the latter study. They included only ten
glaucoma patients (of which six with OAG) and observed
an improvement after a very short follow-up. This suggests
a short-term effect on the sensitivity of the visual system
rather than a real effect on glaucoma progression. More-
over, the observed change was small and did not reach
statistical significance (p = 0.09) [36]. As mentioned in the
Methods section, magnesium absorption competes with
that of phosphorus and calcium; however, we found no
significant interaction between these nutrients (data not
shown). Furthermore, magnesium is present in many fruits,
vegetables, beans and dairy products, and thus, the asso-
ciation of magnesium with OAG might be explained by
other nutrients present in magnesium-rich products.
Table 3 Multivariate analysis for nutrition and open-angle glau-
coma, for all participants and after exclusion of participants taking
supplements
Hazard ratio
(95% CI; p value)
Hazard ratio
(95% CI; p value)*
Age (year) 1.07 (1.04–1.11;
\0.001)
1.09 (1.05–1.14;
\0.001)
Gender 0.74 (0.48–1.15;
0.178)
0.72 (0.41–1.25;
0.243)
IOP (mmHg) 1.16 (1.10–1.22;
\0.001)
1.17 (1.10–1.24;
\0.001)
IOP-lowering
treatment
3.87 (1.95–7.69;
\0.001)
6.21 (2.68–14.41;
\0.001)
Body mass index
(kg/m2)
0.93 (0.87–0.99;
0.026)
0.96 (0.89–1.04;
0.372)
ß-carotene
1st 1.00 (reference) 1.00 (reference)
2nd 1.62 (0.97–2.71;
0.063)
0.99 (0.52–1.86;
0.966)
3rd 1.08 (0.59–2.00;
0.795)
0.97 (0.47–2.00;
0.930)
Retinol equivalents
1st 1.00 (reference) 1.00 (reference)
2nd 1.16 (0.72–1.87;
0.543)
1.04 (0.57–1.89;
0.901)
3rd 0.45 (0.23–0.90;
0.023)
0.33 (0.14–0.80;
0.014)
Vitamin B1
1st 1.00 (reference) 1.00 (reference)
2nd 0.40 (0.21–0.77;
0.006)
0.28 (0.11–0.68;
0.005)
3rd 0.50 (0.25–0.98;
0.044)
0.39 (0.17–0.90;
0.027)
Vitamin B12
1st 1.00 (reference) 1.00 (reference)
2nd 1.60 (0.97–2.64;
0.066)
1.09 (0.55–2.16;
0.800)
3rd 0.95 (0.51–1.78;
0.882)
1.37 (0.65–2.89;
0.415)
Vitamin E
1st 1.00 (reference) 1.00 (reference)
2nd 0.69 (0.39–1.22;
0.199)
0.87 (0.44–1.74;
0.696)
3rd 1.34 (0.81–2.22;
0.250)
1.27 (0.66–2.48;
0.476)
Magnesium
1st 1.00 (reference) 1.00 (reference)
2nd 0.54 (0.27–1.07;
0.076)
0.53 (0.21–1.35;
0.185)
3rd 2.25 (1.16–4.38;
0.016)
3.19 (1.42–7.20;
0.005)
* Participants using supplements were excluded (N = 1302, of which
33 with open-angle glaucoma, leaving 58 open-angle glaucoma cases)
CI confidence interval, IOP intraocular pressure
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Interestingly, the rationale of magnesium substitution is
that magnesium has similar effects as calcium channel
blockers [10, 37]. A double-blind controlled trial with oral
magnesium aspartate HCl supplements, presented an
inverse association with systemic blood pressure [38]. The
role of calcium channel blockers in OAG, however, is all
but clear. Several clinical studies suggested a small pro-
tective effect [39–41], but two large epidemiological
studies including our study reported a harmful effect. These
contradictory findings may be attributed to patient selection
[42, 43]. Adjusting for the use of calcium channel blockers
at baseline did not alter the harmful effect of magnesium in
our study (data not shown). As the influence of calcium
channel blockers on OAG is unclear, it is difficult to
interpret our findings on magnesium.
The strengths of the present study are its population-based
setting and the long follow-up. The study population pre-
sumably consumed a healthy diet as the median nutrient intake
of the study population was at or above the recommended
daily allowance [6]. A possible limitation of our study is that
only one food frequency questionnaire was used at baseline.
Although this could initiate misclassification (dietary changes
may result, amongst others, as part of treatment for chronic
illnesses like hypertension, diabetes mellitus and age-related
macular degeneration), such misclassification would unlikely
result in false-positive findings (none of the illnesses that have
dietary measures as part of its treatment are clearly associated
with OAG). Another possible limitation is the limited number
of participants who developed OAG during follow-up. Almost
half of the cohort deceased or did not participate at follow-up.
Although a selective non-response is possible, we found no
significant differences in dietary intake of nutrients or intake
of supplements between participants and non-participants.
The only relevant differences in baseline characteristics were
age and gender: non-participants were significantly older and
more often women [18]. As high age is associated with an
increased risk of OAG and a decreased dietary intake, non-
participation might have resulted in an underestimation of our
findings. No differences in IOP or body mass index were
observed between participants and non-participants. As we
tested a large number of nutrients, this might have resulted in
false-positive findings. To cope at least partially with this, we
only included nutrients that were earlier addressed in the
literature or for which a clear pathophysiological rationale
could be found (see ‘‘Introduction’’ section). If we would
apply the very strict Bonferroni correction for multiple com-
parisons to the univariate analyses as presented in Table 1, a
p value of 0.003 (0.05/19) would have been considered as
statistically significant in the univariate analysis. According to
Table 1 magnesium and the retinol equivalents are still sig-
nificant at this p value.
The percentage of participants taking supplements in our
study may seem high (36.2–37.2%; Table 1), however, it
was very similar to other studies conducted in the early
nineteens (the baseline of this study). For example, the
National Health and Nutrition Examination Survey reported
that in the age range of 60–69 years, 39.2% of men and
51.6% of women used supplements in the United States [44].
A study from Sweden reported supplement use in 22.2% in
men and 33.3% in women [45]. Finally, we did not adjust for
variables like diabetes mellitus, blood pressure and choles-
terol level, as was done in the Nurses’ Health Study and the
Health Professionals Follow-up Study [11]. However, in the
present study none of these variables showed significant
univariate differences at baseline (p = 0.158, p = 0.976 and
p = 0.682, respectively; Table 1), and thus they would have
been excluded from the final model—if they would have
been included initially. The same holds for smoking; previ-
ously, we reported no association between smoking and
OAG [33]. Although diabetes mellitus was reported not to be
associated with OAG in the Rotterdam Study [46], some
studies suggest the opposite. Furthermore, magnesium has
been associated with diabetes mellitus. For these reasons, we
performed an additional analysis by adding diabetes mellitus
to the model. This did not change the findings (data not
shown).
In conclusion, the current findings suggest that people
with a high intake of retinol equivalents or vitamin B1 have
an about twofold lower risk of OAG compared to those
with a low intake of these nutrients, and people with a high
intake of magnesium have an about threefold increase in
risk of OAG compared to those with a low intake. These
findings might be helpful in the unraveling of the largely
unknown pathophysiology of OAG.
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